Abbott Laboratories (Pakistan)'s quarterly Total Liabilities
declined
from Sep. 2025 (₨16,181.68 Mil) to Dec. 2025 (₨15,190.74 Mil) but then
increased
from Dec. 2025 (₨15,190.74 Mil) to Mar. 2026 (₨16,482.05 Mil).
Abbott Laboratories (Pakistan)'s annual Total Liabilities
declined
from Dec. 2023 (₨18,456.10 Mil) to Dec. 2024 (₨13,926.52 Mil) but then
increased
from Dec. 2024 (₨13,926.52 Mil) to Dec. 2025 (₨15,190.74 Mil).
Abbott Laboratories (Pakistan) Total Liabilities Related Terms
Abbott Laboratories (Pakistan) Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (Pakistan) Total Liabilities Chart
Abbott Laboratories (Pakistan) Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of ₨16,482 Mil mean?
Abbott Laboratories (Pakistan) (KAR:ABOT) has a Total Liabilities of ₨16,482 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Abbott Laboratories (Pakistan) and its competitors.
Is Abbott Laboratories (Pakistan)'s Total Liabilities too high?
Abbott Laboratories (Pakistan)'s current Total Liabilities is ₨16,482 Mil. Overall, Abbott Laboratories (Pakistan) has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories (Pakistan)'s Total Liabilities compare to ZTS and UTHR?
Abbott Laboratories (Pakistan)'s Total Liabilities of ₨16,482 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Abbott Laboratories (Pakistan) and its competitors. Abbott Laboratories (Pakistan)'s current Total Liabilities is ₨16,482 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories (Pakistan) stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) (KAR:ABOT) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,006.12, compared to a current price of ₨997.19 — trading 0.9% below its estimated fair value. The current Total Liabilities is ₨16,482 Mil. Abbott Laboratories (Pakistan)'s overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Abbott Laboratories (Pakistan) (KAR:ABOT), the current Total Liabilities is ₨16,482 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (Pakistan) (KAR:ABOT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) stock appears to be undervalued.
The current stock price of ₨997.19 is trading 0.9% below its estimated GF Value™ of ₨1,006.12.
GuruFocus considers Abbott Laboratories (Pakistan) to be Fairly Valued.
Key valuation signals for KAR:ABOT:
Total Liabilities: ₨16,482 Mil
GF Value™: ₨1,006.12 vs. price of ₨997.19 (0.9% below fair value)
No single metric tells the full story. See the KAR:ABOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott Laboratories (Pakistan) Business Description
Abbott Laboratories (Pakistan) Ltd manufactures, imports, and markets research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. The company's Brands include Duphaston, Brufen, Surbex Z, Arinac, Glucerna, Pediasure, and Ensure.
78GF Score
Get the complete analysis for KAR:ABOT
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:ABOT has been successfully added to your 
